These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. Cohen A; Rovelli A; Merlo DF; van Lint MT; Lanino E; Bresters D; Ceppi M; Bocchini V; Tichelli A; Socié G J Clin Oncol; 2007 Jun; 25(17):2449-54. PubMed ID: 17557958 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Abou-Mourad YR; Lau BC; Barnett MJ; Forrest DL; Hogge DE; Nantel SH; Nevill TJ; Shepherd JD; Smith CA; Song KW; Sutherland HJ; Toze CL; Lavoie JC Bone Marrow Transplant; 2010 Feb; 45(2):295-302. PubMed ID: 19597425 [TBL] [Abstract][Full Text] [Related]
8. Reproductive issues in patients undergoing Hematopoietic Stem Cell Transplantation: an update. Guida M; Castaldi MA; Rosamilio R; Giudice V; Orio F; Selleri C J Ovarian Res; 2016 Nov; 9(1):72. PubMed ID: 27802832 [TBL] [Abstract][Full Text] [Related]
9. What do we need to know about allogeneic hematopoietic stem cell transplant survivors? Clark CA; Savani M; Mohty M; Savani BN Bone Marrow Transplant; 2016 Aug; 51(8):1025-31. PubMed ID: 27064688 [TBL] [Abstract][Full Text] [Related]
10. Late effects of blood and marrow transplantation. Inamoto Y; Lee SJ Haematologica; 2017 Apr; 102(4):614-625. PubMed ID: 28232372 [TBL] [Abstract][Full Text] [Related]
11. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease. Großekatthöfer M; Güclü ED; Lawitschka A; Matthes-Martin S; Mann G; Minkov M; Peters C; Seidel MG Ann Hematol; 2013 Aug; 92(8):1121-8. PubMed ID: 23604429 [TBL] [Abstract][Full Text] [Related]
12. Subsequent malignancies after allogeneic hematopoietic stem cell transplantation. Gündüz M; Özen M; Şahin U; Toprak SK; Civriz Bozdağ S; Kurt Yüksel M; Arslan Ö; Özcan M; Demirer T; Beksaç M; İlhan O; Gürman G; Topçuoğlu P Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28432802 [TBL] [Abstract][Full Text] [Related]
13. Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. Clavert A; Peric Z; Brissot E; Malard F; Guillaume T; Delaunay J; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Harousseau JL; Moreau P; Milpied N; Mohty M; Chevallier P Biol Blood Marrow Transplant; 2017 Jan; 23(1):140-146. PubMed ID: 27751934 [TBL] [Abstract][Full Text] [Related]
14. Chronic graft-versus-host disease and late effects after hematopoietic stem cell transplantation. Sanders JE Int J Hematol; 2002 Aug; 76 Suppl 2():15-28. PubMed ID: 12430895 [TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
17. Complications of allogeneic hematopoietic stem cell transplantation. Arnaout K; Patel N; Jain M; El-Amm J; Amro F; Tabbara IA Cancer Invest; 2014 Aug; 32(7):349-62. PubMed ID: 24902046 [TBL] [Abstract][Full Text] [Related]
18. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant. Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578 [TBL] [Abstract][Full Text] [Related]
19. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156 [TBL] [Abstract][Full Text] [Related]
20. Oral malignancies following HSCT: graft versus host disease and other risk factors. Demarosi F; Lodi G; Carrassi A; Soligo D; Sardella A Oral Oncol; 2005 Oct; 41(9):865-77. PubMed ID: 16084755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]